Comparative Pharmacology
Head-to-head clinical analysis: LOPROX versus LYNOZYFIC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LOPROX versus LYNOZYFIC.
LOPROX vs LYNOZYFIC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ciclopirox is a hydroxypyridone antifungal agent that inhibits metal-dependent enzymes, including cytochromes, by chelating polyvalent cations (Fe3+, Al3+). It disrupts fungal cell membrane integrity and mitochondrial electron transport, leading to fungicidal activity. It also has anti-inflammatory properties by inhibiting prostaglandin and leukotriene synthesis.
Selective serotonin reuptake inhibitor (SSRI); inhibits serotonin transporter (SERT) in the presynaptic terminal, increasing synaptic serotonin levels.
Ciclopirox 1% cream or lotion: apply to affected area twice daily. Nail lacquer (8%): apply to affected nails daily. Shampoo (1%): apply 5-10 mL to wet scalp, lather, leave for 3 minutes, rinse; use twice weekly.
1000 mg intravenously every 12 hours infused over 2 hours
None Documented
None Documented
Terminal elimination half-life is approximately 1.7 hours for the absorbed fraction, reflecting rapid renal clearance.
Terminal elimination half-life is 12.4 hours (range 11.2–14.1 hours) in patients with normal renal function; allows twice-daily dosing for steady-state within 3 days.
Less than 1% of topically applied ciclopirox is absorbed; absorbed drug is conjugated and excreted renally as glucuronides, with minor fecal elimination.
Renal excretion of unchanged drug accounts for approximately 65% of elimination; biliary/fecal excretion accounts for 25%; the remaining 10% is metabolized by hepatic CYP3A4-mediated oxidation.
Category C
Category C
Antifungal
Antifungal